Osimo et al. developed two models to predict the risk of treatment-resistant schizophrenia in patients with a first-episode psychosis using blood-based biomarkers and sociodemographic data routinely collected at psychosis onset in psychosis early intervention services in the United Kingdom. They used clozapine treatment as a proxy for treatment-resistant schizophrenia using data from 785 patients for model development and 1,110 patients for external validation.
- Emanuele F. Osimo
- Benjamin I. Perry
- Golam M. Khandaker
